Prucalopride for the treatment of chronic constipation in women

  • Technology appraisal guidance
  • TA211
  • Published: 
Download guidance (PDF)

7 Sources of evidence considered by the Committee

The Evidence Review Group (ERG) report for this appraisal was prepared by West Midlands Health Technology Assessment Collaboration (WMHTAC):

  • Pennant M, Orlando R, Barton P et al. Prucalopride for the treatment of women with chronic constipation in whom standard laxative regimens have failed to provide adequate relief, June 2010

The following organisations accepted the invitation to participate in this appraisal as consultees and commentators. They were invited to comment on the draft scope, the ERG report and the appraisal consultation document (ACD). Manufacturers or sponsors were also invited to make written submissions. Professional or specialist, and patient or carer groups, and other consultees had the opportunity to give their expert views. Manufacturers or sponsors, professional or specialist, patient or carer groups, and other consultees also have the opportunity to appeal against the final appraisal determination.

Manufacturer or sponsor:

  • Movetis

Professional or specialist, and patient or carer groups:

  • PromoCon

  • Association of Continence Advice

  • British Society of Gastroenterology

  • Royal College of Nursing

  • Royal College of Physicians

Other consultees:

  • Department of Health

  • NHS Greenwich

  • Welsh Assembly Government

Commentator organisations (did not provide written evidence and without the right of appeal):

  • Commissioning Support Appraisals Service

  • Department of Health, Social Services and Public Safety for Northern Ireland

  • NHS Quality Improvement Scotland

  • Napp Pharmaceuticals (dantron)

  • Norgine Pharmaceuticals (sterculia/frangula, macrogol, docusate sodium enema)

  • National Institute for Health Research Health Technology Assessment Programme

  • West Midlands Health Technology Assessment Collaboration (WMHTAC)

The following individuals were selected from clinical specialist and patient expert nominations from the non-manufacturer or sponsor consultees and commentators. They gave their expert personal view on prucalopride for the treatment of chronic constipation in women by attending the initial Committee discussion and providing written evidence to the Committee. They were also invited to comment on the ACD.

  • Dr Anton Emmanuel, Senior Lecturer and Hon Consultant Gastroenterologist, nominated by British Society of Gastroenterology – clinical specialist

  • Professor Peter Whorwell, Professor of Medicine and Gastroenterology, nominated by Movetis – clinical specialist

  • June Rogers MBE, Team Director, nominated by PromoCon – patient expert

The following individuals were nominated as NHS Commissioning experts by the selected NHS Trust allocated to this appraisal. They gave their NHS commissioning personal view on prucalopride for the treatment of chronic constipation in women by attending the initial Committee discussion and providing written evidence to the Committee. They were also invited to comment on the ACD.

  • Rena Amin, Joint Head of Medicines Management selected by NHS Greenwich – NHS Commissioning expert

Representatives from the following manufacturer or sponsor attended Committee Meetings. They contributed only when asked by the Committee chair to clarify specific issues and comment on factual accuracy.

  • Movetis